tbuckley/cabot-search huggingface dataset:
Association Between Obstructive Sleep Apnea and Brain White Matter Hyperintensities in a Population-Based Cohort in Germany
Authors: Helena U. Zacharias, Antoine Weihs, Mohamad Habes, Katharina Wittfeld, Stefan Frenzel, Tanweer Rashid, Beate Stubbe, Anne Obst, András Szentkirályi, Robin Bülow, Klaus Berger, Ingo Fietze, Thomas Penzel, Norbert Hosten, Ralf Ewert, Henry Völzke, Hans J. Grabe
Journal: JAMA Network Open (2021)

Underlying pathomechanisms of brain white matter hyperintensities (WMHs), commonly observed in older individuals and significantly associated with Alzheimer disease and brain aging, have not yet been fully elucidated. One potential contributing factor to WMH burden is chronic obstructive sleep apnea (OSA), a disorder highly prevalent in the general population with readily available treatment options.To investigate potential associations between OSA and WMH burden.Analyses were conducted in 529 study participants of the Study of Health in Pomerania-Trend baseline (SHIP-Trend-0) study with complete WMH, OSA, and important clinical data available. SHIP-Trend-0 is a general population-based, cross-sectional, observational study to facilitate the investigation of a large spectrum of common risk factors, subclinical disorders, and clinical diseases and their relationships among each other with patient recruitment from Western Pomerania, Germany, starting on September 1, 2008, with data collected until December 31, 2012. Data analysis was performed from February 1, 2019, to January 31, 2021.The apnea-hypopnea index (AHI) and oxygen desaturation index (ODI) were assessed during a single-night, laboratory-based polysomnography measurement.The primary outcome was WMH data automatically segmented from 1.5-T magnetic resonance images.Of 529 study participants (mean [SD] age, 52.15 [13.58] years; 282 female [53%]), a total of 209 (40%) or 102 (19%) individuals were diagnosed with OSA according to AHI or ODI criteria (mean [SD] AHI, 7.98 [12.55] events per hour; mean [SD] ODI, 3.75 [8.43] events per hour). Both AHI (β = 0.024; 95% CI, 0.011-0.037; P <.001) and ODI (β = 0.033; 95% CI, 0.014-0.051; P <. 001) were significantly associated with brain WMH volumes. These associations remained even in the presence of additional vascular, metabolic, and lifestyle WMH risk factors. Region-specific WMH analyses found the strongest associations between periventricular frontal WMH volumes and both AHI (β = 0.0275; 95% CI, 0.013-0.042, P < .001) and ODI (β = 0.0381; 95% CI, 0.016-0.060, P < .001) as well as periventricular dorsal WMH volumes and AHI (β = 0.0165; 95% CI, 0.004-0.029, P = .008).This study found significant associations between OSA and brain WMHs, indicating a novel, potentially treatable WMH pathomechanism.
341O A phase 0 ‘Trigger’ trial of CDK4/6 plus ERK1/2 inhibitors in recurrent glioblastoma
Authors: S.N. Mehta, N. Sanai, Y-W. Chang, T. Margaryan, A. DeSantis, M. Elliott, C. Pennington-Krygier, G. Hook, W. Yoo, A-C. Tien, A. Tovmasyan
Journal: Annals of Oncology (2021)
277P Phase II randomized study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with HR-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B
Authors: H. Masuda, Y. Tanabe, K. Matsumoto, A. Shimomura, M. Doi, Y. Miyoshi, M. Takahashi, Y. Sagara, S. Tokunaga, T. Iwasa, N. Niikura, K. Yoshimura, T. Takano, J. Tsurutani
Journal: Annals of Oncology (2021)
Unravelling the origins of musicality: Beyond music as an epiphenomenon of language
Authors: Henkjan Honing
Journal: Behavioral and Brain Sciences (2021)

Abstract The two target articles address the origins of music in complementary ways. However, both proposals focus on overt musical behaviour, largely ignoring the role of perception and cognition, and they blur the boundaries between the potential origins of language and music. To resolve this, an alternative research strategy is proposed that focuses on the core cognitive components of musicality.
Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity—Reply
Authors: Ildiko Lingvay, W. Timothy Garvey, Thomas A. Wadden
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human evolution of gestural messaging and its critical role in the human development of music
Authors: Martin F Gardiner
Journal: Behavioral and Brain Sciences (2021)

Abstract By fostering bonding (Mehr et al.; Savage et al.), music illustrates marvelously its ability to induce emotional experience. But, music can induce emotion more generally as well. To help explain how music fosters bonding and induces other emotions, I propose that music derives this power from the evolution of what I term “gestural messaging.”
Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865–878]
Authors: Roser Pinyol, Sara Torrecilla, Huan Wang, Carla Montironi, Marta Piqué-Gili, Miguel Torres-Martin, Leow Wei-Qiang, Catherine E. Willoughby, Pierluigi Ramadori, Carmen Andreu-Oller, Patricia Taik, Youngmin A. Lee, Agrin Moeini, Judit Peix, Suzanne Faure-Dupuy, Tobias Riedl, Svenja Schuehle, Claudia P. Oliveira, Venancio A. Alves, Paolo Boffetta, Anja Lachenmayer, Stephanie Roessler, Beatriz Minguez, Peter Schirmacher, Jean-François Dufour, Swan N. Thung, Helen L. Reeves, Flair J. Carrilho, Charissa Chang, Andrew V. Uzilov, Mathias Heikenwalder, Arun Sanyal, Scott L. Friedman, Daniela Sia, Josep M. Llovet
Journal: Journal of Hepatology (2021)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Authors: William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M. Pagel, Ian Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer-Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia, Constantine S. Tam
Journal: Journal of Clinical Oncology (2021)

CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL).Previously untreated CLL patients age < 70 years received three cycles of ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD cohort who met the stringent random assignment criteria for confirmed undetectable MRD (Confirmed uMRD) were randomly assigned 1:1 to double-blind placebo or ibrutinib; patients without Confirmed uMRD (uMRD Not Confirmed) were randomly assigned 1:1 to open-label ibrutinib or ibrutinib plus venetoclax. Primary end point was 1-year disease-free survival (DFS) rate with placebo versus ibrutinib in the Confirmed uMRD population. Secondary end points included response rates, uMRD, and safety.One hundred sixty-four patients initiated three cycles of ibrutinib lead-in. After 12 cycles of ibrutinib plus venetoclax, best uMRD response rates were 75% (peripheral blood) and 68% (bone marrow). Patients with Confirmed uMRD were randomly assigned to receive placebo (n = 43) or ibrutinib (n = 43); patients with uMRD Not Confirmed were randomly assigned to ibrutinib (n = 31) or ibrutinib plus venetoclax (n = 32). Median follow-up was 31.3 months. One-year DFS rate was not significantly different between placebo (95%) and ibrutinib (100%; arm difference: 4.7% [95% CI, -1.6 to 10.9]; P = .15) in the Confirmed uMRD population. After ibrutinib lead-in tumor debulking, 36 of 40 patients (90%) with high tumor lysis syndrome risk at baseline shifted to medium or low tumor lysis syndrome risk categories. Adverse events were most frequent during the first 6 months of ibrutinib plus venetoclax and generally decreased over time.The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, once-daily, chemotherapy-free regimen in first-line CLL.
The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis
Authors: Oriol Alejo-Valle, Karoline Weigert, Raj Bhayadia, Michelle Ng, Hasan Issa, Christoph Beyer, Stephan Emmrich, Konstantin Schuschel, Christian Ihling, Andrea Sinz, Martin Zimmermann, Claudia Wickenhauser, Marius Flasinski, Eniko Regenyi, Maurice Labuhn, Dirk Reinhardt, Marie-Laure Yaspo, Dirk Heckl, Jan-Henning Klusmann
Journal: Blood (2021)

Given the plasticity of hematopoietic stem and progenitor cells, multiple routes of differentiation must be blocked in the the pathogenesis of acute myeloid leukemia, the molecular basis of which is incompletely understood. We report that posttranscriptional repression of the transcription factor ARID3A by miR-125b is a key event in the pathogenesis of acute megakaryoblastic leukemia (AMKL). AMKL is frequently associated with trisomy 21 and GATA1 mutations (GATA1s), and children with Down syndrome are at a high risk of developing the disease. The results of our study showed that chromosome 21-encoded miR-125b synergizes with Gata1s to drive leukemogenesis in this context. Leveraging forward and reverse genetics, we uncovered Arid3a as the main miR-125b target behind this synergy. We demonstrated that, during normal hematopoiesis, this transcription factor promotes megakaryocytic differentiation in concert with GATA1 and mediates TGFβ-induced apoptosis and cell cycle arrest in complex with SMAD2/3. Although Gata1s mutations perturb erythroid differentiation and induce hyperproliferation of megakaryocytic progenitors, intact ARID3A expression assures their megakaryocytic differentiation and growth restriction. Upon knockdown, these tumor suppressive functions are revoked, causing a blockade of dual megakaryocytic/erythroid differentiation and subsequently of AMKL. Inversely, restoring ARID3A expression relieves the arrest of megakaryocytic differentiation in AMKL patient-derived xenografts. This work illustrates how mutations in lineage-determining transcription factors and perturbation of posttranscriptional gene regulation can interact to block multiple routes of hematopoietic differentiation and cause leukemia. In AMKL, surmounting this differentiation blockade through restoration of the tumor suppressor ARID3A represents a promising strategy for treating this lethal pediatric disease.
Construction of pH‐Dependent Nanozymes with Oxygen Vacancies as the High‐Efficient Reactive Oxygen Species Scavenger for Oral‐Administrated Anti‐Inflammatory Therapy
Authors: Ning Zhao, Fei‐Er Yang, Cong‐Ying Zhao, Shi‐Wen Lv, Jin Wang, Jing‐Min Liu, Shuo Wang
Journal: Advanced Healthcare Materials (2021)

Abstract It is of great significance to eliminate excessive reactive oxygen species (ROS) for treating inflammatory bowel disease (IBD). Herein, for the first time, a novel nanozyme NiCo 2 O 4 @PVP is constructed via a step‐by‐step strategy. Noticeably, the existence of oxygen vacancy in the NiCo 2 O 4 @PVP is helpful for capturing oxygenated compounds, while both redox couples of Co 3+ /Co 2+ and Ni 3+ /Ni 2+ will offer richer catalytic sites. As expected, the obtained NiCo 2 O 4 @PVP exhibits pH‐dependent multiple mimic enzymatic activities. Benefiting from the introduction of polyvinylpyrrolidone (PVP), the NiCo 2 O 4 @PVP possesses good physiological stability and excellent biosafety in stomach and intestines’ environment. Meanwhile, the NiCo 2 O 4 @PVP also presents strong scavenging activities to ROS in vitro, including • O 2 − , H 2 O 2 , as well as • OH. Furthermore, a dextran sodium sulfate (DSS)‐induced colitis model is established for evaluating the anti‐inflammatory activity of NiCo 2 O 4 @PVP in vivo. Based on the size‐mediated and charge‐mediated mechanisms, the nanozyme can pass through the digestive tract and target the inflamed site for oral‐administrated anti‐inflammatory therapy. More interestingly, compared with the model group, the expression levels of inflammatory factors (e.g., Interleukin‐ 6 (IL‐6), Interleukin‐ 1β (IL‐1 β) , tumor necrosis factor‐α (TNF‐ α ), and inducible nitric oxide synthase (iNOS)) in colon of mice show a significant decrease after nanozyme intervention, thereby inhibiting the development of IBD. In short, current work provides an alternative therapy for patients suffering from IBD.
423P From clinical trial to bedside: Triplet chemotherapy (FOLFOXIRI-B) in metastatic colorectal cancer
Authors: G.M. Bol, S.C.M.W. van Nassau, M. Bond, I. Scheerman, J.V. Breeschoten, R. Kessels, L. Valkenburg-van Iersel, H.M.W. Verheul, T. Buffart, L.J.M. Mekenkamp, V. Lemmens, M. Koopman
Journal: Annals of Oncology (2021)
1201P Real-world comparative effectiveness of 1L alectinib (ALC) vs crizotinib (CRZ) in patients (pts) with ALK+ advanced NSCLC with or without baseline CNS metastases (mets)
Authors: M.G. Krebs, J.J. Lin, N. Pal, L. Polito, H.T.L. Trinh, M.M.S.M. Hilton, V. Smoljanovic, N. Kurtsikidze, V. Archer, Q. Zhang
Journal: Annals of Oncology (2021)
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations
Authors: Stefano Aliberti, Pieter C Goeminne, Anne E O'Donnell, Timothy R Aksamit, Hamdan Al-Jahdali, Alan F Barker, Francesco Blasi, Wim G Boersma, Megan L Crichton, Anthony De Soyza, Katerina E Dimakou, Stuart J Elborn, Charles Feldman, Harm Tiddens, Charles S Haworth, Adam T Hill, Michael R Loebinger, Miguel Angel Martinez-Garcia, Jennifer J Meerburg, Rosario Menendez, Lucy C Morgan, Marlene S Murris, Eva Polverino, Felix C Ringshausen, Michal Shteinberg, Nicola Sverzellati, Gregory Tino, Antoni Torres, Thomas Vandendriessche, Montserrat Vendrell, Tobias Welte, Robert Wilson, Conroy A Wong, James D Chalmers
Journal: The Lancet Respiratory Medicine (2021)
Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents
Authors: Eliseo Albert, Javier S. Burgos, Salvador Peiró, Dolores Salas, Hermelinda Vanaclocha, Estela Giménez, Ramón Limón, María Jesús Alcaraz, José Sánchez-Payá, Javier Díez-Domingo, David Navarro, J.S. Burgos, R. Meneu de Guillerna, H. Vanaclocha Luna, D.J. Burks, A. Cervantes, I. Comas, J. Díez-Domingo, S. Peiro, F. González-Candelas, C. Ferrer Albiach, I. Hernández-Aguado, N. Oliver Ramírez, J. Sánchez-Payá, M. Vento Torres, E. Zapater Latorre, D. Navarro
Journal: Clinical Microbiology and Infection (2021)
967P The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer
Authors: A. Vilalta, H. Arasanz, M. Rodriguez-Remirez, I. Lopez, A. Puyalto, A. Lecumberri, I. Baraibar, J. Corral, A. Gúrpide, J.L. Perez-Gracia, J.M. López-Picazo, M.P. Andueza, V. Catalán, G. Frühbeck, R. Pío, D. Ajona, I. Gil Bazo
Journal: Annals of Oncology (2021)
7MO Effect of anti-CTLA-4 immunotherapy on lymphocyte subset and activation profiles and clonal composition on the B16F0 mouse melanoma model
Authors: D.V. Yuzhakova, A.V. Izosimova, G.V. Sharonov, L.N. Volchkova, I.A. Shagina, M.A. Izraelson, A.N. Davydov, V. Skatova, D.M. Chudakov
Journal: Annals of Oncology (2021)
1276P Deep molecular characterization of never smoker non-small cell lung cancer (NSCLC) patients
Authors: C. Dellepiane, G. De Luca, M. Tagliamento, S. Coco, G. Rossi, M.G. Dal Bello, M. Mora, L. Zullo, A. Alama, A. Bottini, G. Sacco, E. Cella, E. Bennicelli, R. Borea, V. Murianni, F. Parisi, S. Salvi, P. Pronzato, M. Dono, C. Genova
Journal: Annals of Oncology (2021)
217P The impact of obesity on the survival outcomes of women with breast cancer that achieve pathological complete response
Authors: M. Roman-Zamudio, A. Aranda Gutierrez, A.S. Ferrigno, A. Becerril-Gaitan, B.F. Vaca-Cartagena, F.A. Gonzalez-Mondellini, M.A. Acosta-Sandoval, M.I. Torres-Leal, H.M. Diaz-Perez, S. Cardona-Huerta, R. Ortiz-López, C. Villarreal-Garza
Journal: Annals of Oncology (2021)
The hippocampus converts dynamic entorhinal inputs into stable spatial maps
Authors: Thibault Cholvin, Thomas Hainmueller, Marlene Bartos
Journal: Neuron (2021)

The medial entorhinal cortex (MEC)-hippocampal network plays a key role in the processing, storage, and recall of spatial information. However, how the spatial code provided by MEC inputs relates to spatial representations generated by principal cell assemblies within hippocampal subfields remains enigmatic. To investigate this coding relationship, we employed two-photon calcium imaging in mice navigating through dissimilar virtual environments. Imaging large MEC bouton populations revealed spatially tuned activity patterns. MEC inputs drastically changed their preferred spatial field locations between environments, whereas hippocampal cells showed lower levels of place field reconfiguration. Decoding analysis indicated that higher place field reliability and larger context-dependent activity-rate differences allow low numbers of principal cells, particularly in the DG and CA1, to provide information about location and context more accurately and rapidly than MEC inputs. Thus, conversion of dynamic MEC inputs into stable spatial hippocampal maps may enable fast encoding and efficient recall of spatio-contextual information.
1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
Authors: T. Bekaii-Saab, T. Okusaka, D. Goldstein, D-Y. Oh, M. Ueno, T. Ioka, W. Fang, E.C. Anderson, M.S. Noel, M. Reni, H.J. Choi, J. Goldberg, S.C. Oh, C-P. Li, J. Tabernero, J. Li, E. Foos, C. Oh, E. Van Cutsem
Journal: Annals of Oncology (2021)
1077P Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE)
Authors: G.V. Long, H.A. Tawbi, N. Meyer, B. Breznen, C. Vyas, L. Leung, A. Moshyk, D. Pushkarna, P. Thakkar, M.S. Fazeli, S. Kotapati, D. Schadendorf
Journal: Annals of Oncology (2021)
Clarifying the link between music and social bonding by measuring prosociality in context
Authors: Matthew E. Sachs, Oriel FeldmanHall, Diana I. Tamir
Journal: Behavioral and Brain Sciences (2021)

Abstract To corroborate the music and social bonding hypothesis, we propose that future investigations isolate specific components of social bonding and consider the influence of context. We deconstruct and operationalize social bonding through the lens of social psychology and provide examples of specific measures that can be used to assess how the link between music and sociality varies by context.
Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment
Authors: Etienne Lengliné, Julien Peron, Antoine Vanier, François Gueyffier, Serge Kouzan, Patrick Dufour, Bernard Guillot, Hugues Blondon, Michel Clanet, Pierre Cochat, Françoise Degos, Sylvie Chevret, Mathilde Grande, Jade Putzolu
Journal: The Lancet Oncology (2021)
Oral Upadacitinib Beats Subcutaneous Dupilumab for Atopic Dermatitis
Authors: Anita Slomski
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
480P Gene expression of NANOG and NANOGP8 in colorectal cancer
Authors: H. Arai, Y. Baca, J. Xiu, F. Battaglin, J. Hwang, J.L. Marshall, R.M. Goldberg, B.A. Weinberg, D. Sohal, E. Lou, M.J. Hall, J. Wang, N. Kawanishi, P. Jayachandran, S. Soni, W. Zhang, D. Magee, W.M. Korn, H.J. Lenz
Journal: Annals of Oncology (2021)
1408P Efficacy of immunotherapy in the first line treatment of advanced upper gastrointestinal tract malignancies: A pooled analysis of randomized clinical trials
Authors: P. Ntellas, K. Kamposioras, I. Gazouli, T. Germataki, K. Dadouli, G. Zarkavelis, A.L. Amylidi, L. Mavroeidis, S. Gkoura, M. Tolia, D. Mauri
Journal: Annals of Oncology (2021)
887P Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Authors: S-B. Kim, B. Keam, S-H. Shin, Y. Chae, S. Seo, K. Park, T.M. Kim, L.C. Park, S-B. Hong, M-J. Ahn
Journal: Annals of Oncology (2021)
868P A phase II trial of induction chemotherapy (IC), photon-, proton- and carbon ion-based radiotherapy (RT) integration in locally advanced inoperable sinonasal epithelial tumors patients (pts)
Authors: P. Bossi, C. Resteghini, E. Orlandi, P. Nicolai, B. Vischioni, P. Castelnuovo, M. Turri-Zanoni, M. Ferrari, V. Rampelli, N. Facchinetti, S. Gambazza, G. Calareso, P. Quattrone, R. Ingargiola, A. Cavallo, M. Franceschini, A. Tuzi, L. Mariani, L.F. Licitra
Journal: Annals of Oncology (2021)